The effect of angiotensin II on blood pressure in patients with circulatory shock: A structured review of the literature

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Busse, Laurence W ^a   McCurdy, Michael T ^b   Ali, Osman ^b   Hall, Anna ^c   Chen, Huaizhen ^a   Ostermann, Marlies ^c  

^a and Sleep Medicine ^*  (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Angiotensin II; Cardiac arrest; Cardiogenic shock; Distributive shock; Vasoconstrictor; Vasopressor

Indexed keywords

ANGIOTENSIN II; VASOACTIVE AGENT;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOGENIC SHOCK; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; HEART ARREST; HUMAN; HYPOTENSION; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RETURN OF SPONTANEOUS CIRCULATION; SEPTIC SHOCK; SHOCK; SYSTEMATIC REVIEW; URINE VOLUME; MORTALITY; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PROCEDURES;

ANGIOTENSIN II; BLOOD PRESSURE; HUMANS; MONITORING, PHYSIOLOGIC; SHOCK;

EID: 85039543404     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1896-6     Document Type: Article

References (65)

1. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2, CD003709.
2. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-89.
3. Hiltebrand LB, Krejci V, Jakob SM, Takala J, Sigurdsson GH. Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology. 2007;106(6):1156-67.
4. Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950-8.
5. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313-9.
6. Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, De Backer D, Payen D. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34(3):589-97.
7. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226-34.
8. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-87.
9. Zhou F, Mao Z, Zeng X, Kang H, Liu H, Pan L, Hou PC. Vasopressors in septic shock: a systematic review and network meta-analysis. Ther Clin Risk Manag. 2015;11:1047-59.
10. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.
11. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-30.
12. Campbell DJ. Do intravenous and subcutaneous angiotensin II increase blood pressure by different mechanisms? Clin Exp Pharmacol Physiol. 2013;40(8):560-70.
13. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin ii and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171-86.
14. Oelkers W, Schoneshofer M, Schultze G, Brown JJ, Fraser R, Morton JJ, Lever AF, Robertson JI. Effect of prolonged low-dose angiotensin II infusion on the sensitivity of adrenal cortex in man. Circ Res. 1975;36(6 Suppl 1):49-56.
15. Conti C, Tranquilli AL, Garzetti GG, Romanini C. Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion. Boll Soc Ital Biol Sper. 1994;70(10-11):243-8.
16. Oney T, Kaulhausen H. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy. Am J Obstet Gynecol. 1982;142(1):17-20.
17. Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child. 2000;82(5):388-9.
18. Cumming GR. Acute hemodynamic effects of angiotensin II. Preliminary report. Can Med Assoc J. 1963;88:827-32.
19. Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, Yoo D, Dana SL, Chawla LS. Clinical eexperience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285-94.
20. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341(8846):703.
21. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165-8.
22. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40(1):103-4.
23. Tovar JL, Bujons I, Ruiz JC, Ibanez L, Salgado A. Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron. 1997;77(2):239.
24. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;346(8990):1604.
25. Del Greco F, Johnson DC. Clinical experience with angiotensin II in the treatment of shock. JAMA. 1961;178:994-9.
26. Udhoji VN, Weil MH. Circulatory effects of angiotensin, levarterenol and metaraminol in the treatment of shock. N Engl J Med. 1964;270:501-5.
27. Cohn JN, Luria MH. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran. Arch Intern Med. 1965;116(4):562-6.
28. Singh S, Malhotra RP. Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). J Assoc Physicians India. 1966;14(11):639-45.
29. Wallace JM, Lopez G, Malo-Camacho R, DeLeon JA, Walker JP, Kirksey TD, Derrick JR. Hemodynamic effects of angiotensin during surgical anesthesia. Am Heart J. 1967;73(3):326-33.
30. Eyraud D, Mouren S, Teugels K, Bertrand M, Coriat P. Treating anesthesia-induced hypotension by angiotensin II in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1998;86(2):259-63.
31. Cohn JN, Luria MH. Studies in clinical shock and hypotension. ii. hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44:1494-504.
32. Sorensen SS, Danielsen H, Jespersen B, Pedersen EB. Hypotension in end-stage renal disease: effect of postural change, exercise and angiotensin II infusion on blood pressure and plasma concentrations of angiotensin II, aldosterone and arginine vasopressin in hypotensive patients with chronic renal failure treated by dialysis. Clin Nephrol. 1986;26(6):288-96.
33. Moore TJ, Lazarus JM, Hakim RM. Reduced angiotensin receptors and pressor responses in hypotensive hemodialysis patients. Kidney Int. 1989;36(4):696-701.
34. Nassif AC, Nolan TR, Corcoran AC. Angiotensin II in treatment of hypotensive states. JAMA. 1963;183:751-4.
35. Wedeen R, Zucker G. Angiotensin II in the treatment of shock. Am J Cardiol. 1963;11:82-6.
36. Beanlands DS, Gunton RW. Angiotensin ii in the treatment of shock following myocardial infarction. Am J Cardiol. 1964;14:370-3.
37. Belle MS, Jaffee RJ. The use of large doses of angiotensin in acute myocardial infarction with shock. J Lancet. 1965;85:193-4.
38. Geary VM, Thaker UN, Chalmers PC, Sheikh F. The use of angiotensin II to treat profound hypotension in a patient taking amiodarone. J Cardiothorac Anesth. 1990;4(3):364-7.
39. Thaker U, Geary V, Chalmers P, Sheikh F. Low systemic vascular resistance during cardiac surgery: case reports, brief review, and management with angiotensin II. J Cardiothorac Anesth. 1990;4(3):360-3.
40. Thomas VL, Nielsen MS. Administration of angiotensin II in refractory septic shock. Crit Care Med. 1991;19(8):1084-6.
41. Ryding J, Heslet L, Hartvig T, Jonsson V. Reversal of 'refractory septic shock' by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest. 1995;107(1):201-3.
42. Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS, Velissaris D, Scolletta S. Angiotensin II in refractory septic shock. Shock. 2017;47(5):560-6.
43. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-70.
44. Hall JE, Coleman TG, Guyton AC, Kastner PR, Granger JP. Control of glomerular filtration rate by circulating angiotensin II. Am J Phys. 1981;241(3):R190-7.
45. Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Phys. 1984;246(6 Pt 2):F897-906.
46. Whiteley SM, Dade JP. Treatment of hypotension in septic shock. Lancet. 1996;347(9001):622.
47. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96(11):4065-82.
48. Basu U, Seravalli J, Madayiputhiya N, Adamec J, Case AJ, Zimmerman MC. Rapid metabolism of exogenous angiotensin II by catecholaminergic neuronal cells in culture media. Physiol Rep. 2015;3(2).
49. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63(3):423-32.
50. Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, et al. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. Circulation. 1993;88(2):481-91.
51. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53-7.
52. van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106(3):367-72.
53. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension. 2001;38(2):177-82.
54. Salgado DR, Rocco JR, Silva E, Vincent JL. Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Expert Opin Ther Targets. 2010;14(1):11-20.
55. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
56. Liu YJ, Shnkley NP, Welsh NJ, Black JW. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35.
57. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997;319(1):137-46.
58. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999;39(6):547-59.
59. Wang G, Zhang Q, Yuan W, Wu J, Li C. Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation. Int J Mol Med. 2016;38(5):1463-73.
60. Bjerregaard J, Jaffe RA. Intraoperative cardiac arrest: was it the ACE inhibitor? J Clin Anesth. 2014;26(1):62-4.
61. Dhingra R, Kirshenbaum LA. Negative inotropy by angiotensin II is mediated via phosphoinositide 3-kinase alpha-protein kinase C-coupled signaling pathway. Hypertension. 2010;56(3):349-50.
62. Liang W, Oudit GY, Patel MM, Shah AM, Woodgett JR, Tsushima RG, Ward ME, Backx PH. Role of phosphoinositide 3-kinase α, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension. 2010;56(3):422-9.
63. Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, Zelis R. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest. 1994;93(2):684-91.
64. Lyons D, Webster J, Benjamin N. Angiotensin II. Adrenergic sympathetic constrictor action in humans. Circulation. 1995;91(5):1457-60.
65. Paradis NA, Martin GB, Rivers EP, Goetting MG, Appleton TJ, Feingold M, Nowak RM. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA. 1990;263(8):1106-13.